Thomas Powles Selected Research

B7-H1 Antigen

1/2022	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
1/2022	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
1/2021	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
1/2021	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
1/2021	PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
1/2021	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial.
1/2021	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
10/2020	Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.
1/2020	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
10/2019	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Powles Research Topics

Disease

110	Renal Cell Carcinoma (Grawitz Tumor) 10/2022 - 03/2010
104	Neoplasms (Cancer) 10/2022 - 01/2004
58	Carcinoma (Carcinomatosis) 05/2022 - 06/2013
40	Kidney Neoplasms (Kidney Cancer) 10/2022 - 09/2008
33	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 01/2007
20	Disease Progression 10/2022 - 09/2011
18	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2010
13	Fatigue 01/2021 - 11/2012
12	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 12/2007
8	Hypertension (High Blood Pressure) 01/2022 - 07/2016
7	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2017 - 06/2010
5	Urologic Neoplasms (Urological Cancer) 10/2020 - 01/2019
4	Diarrhea 06/2022 - 05/2014
4	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 10/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2018
3	Neutropenia 12/2020 - 01/2009
3	COVID-19 08/2020 - 01/2020
3	Nausea 10/2018 - 08/2014
3	Hypoxia (Hypoxemia) 10/2016 - 12/2012
3	HIV Infections (HIV Infection) 02/2009 - 09/2008
2	Urinary Tract Infections (Urinary Tract Infection) 06/2022 - 01/2021
2	Inflammation (Inflammations) 01/2022 - 01/2020
2	Colitis 01/2021 - 11/2017
2	Sepsis (Septicemia) 01/2021 - 11/2017
2	Body Weight (Weight, Body) 01/2021 - 04/2018
2	Hepatitis 12/2020 - 03/2008
2	Pain (Aches) 11/2020 - 11/2014
2	Non-Muscle Invasive Bladder Neoplasms 01/2018 - 03/2017
2	Thrombosis (Thrombus) 01/2016 - 05/2015

Drug/Important Bio-Agent (IBA)

57	Sunitinib (Sutent)FDA Link 10/2022 - 09/2008
42	Immune Checkpoint InhibitorsIBA 02/2022 - 05/2017
39	atezolizumabIBA 03/2022 - 11/2014
31	Cisplatin (Platino)FDA LinkGeneric 05/2022 - 01/2007
31	PlatinumIBA 05/2022 - 01/2007
28	NivolumabIBA 01/2022 - 01/2016
27	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2011
26	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022 - 06/2012
22	pembrolizumabIBA 10/2022 - 03/2017
21	IpilimumabIBA 01/2022 - 03/2018
19	B7-H1 AntigenIBA 01/2022 - 11/2014
17	cabozantinibIBA 01/2022 - 11/2015
16	Everolimus FDA Link 09/2021 - 08/2014
13	LigandsIBA 02/2022 - 10/2015
12	avelumabIBA 06/2022 - 03/2017
12	pazopanib FDA Link 11/2020 - 11/2012
11	Axitinib (AG 013736)IBA 10/2022 - 01/2018
11	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2010
10	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2013
9	Bevacizumab (Avastin)FDA Link 02/2022 - 01/2018
8	Pharmaceutical PreparationsIBA 01/2022 - 01/2007
8	durvalumabIBA 01/2022 - 03/2017
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021 - 11/2015
7	Docetaxel (Taxotere)FDA Link 01/2021 - 03/2015
6	Gemcitabine FDA Link 05/2022 - 06/2013
6	Carboplatin (JM8)FDA LinkGeneric 05/2022 - 01/2007
5	RamucirumabIBA 01/2022 - 11/2017
5	Monoclonal AntibodiesIBA 01/2022 - 01/2018
4	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 09/2015
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 06/2017
4	Lipase (Acid Lipase)FDA Link 01/2021 - 01/2018
4	Alanine Transaminase (SGPT)IBA 12/2020 - 03/2016
4	TOR Serine-Threonine KinasesIBA 01/2017 - 11/2014
3	lenvatinibIBA 10/2021 - 03/2019
3	enfortumab vedotinIBA 06/2021 - 01/2021
3	tremelimumabIBA 01/2021 - 12/2020
3	vinflunineIBA 01/2021 - 01/2018
3	AntibodiesIBA 10/2019 - 01/2018
3	ErbB Receptors (EGF Receptor)IBA 11/2017 - 03/2010
3	Lapatinib (GW572016)FDA Link 11/2017 - 12/2010
3	Irinotecan (Camptosar)FDA LinkGeneric 10/2014 - 09/2008
2	EnzymesIBA 01/2022 - 01/2021
2	enzalutamideIBA 01/2022 - 03/2015
2	Hormones (Hormone)IBA 01/2022 - 12/2014
2	Biological ProductsIBA 12/2021 - 09/2015
2	Complement System Proteins (Complement)IBA 10/2021 - 01/2021
2	Interleukin-8 (Interleukin 8)IBA 03/2021 - 01/2020
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2020
2	Programmed Cell Death 1 ReceptorIBA 01/2021 - 10/2015
2	Mechanistic Target of Rapamycin Complex 1IBA 01/2021 - 10/2016
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2020 - 11/2017
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2018
2	Amylases FDA Link 10/2019 - 01/2018
2	Therapeutic UsesIBA 10/2019 - 01/2017
2	Sorafenib (BAY 43-9006)FDA Link 11/2018 - 01/2013
2	sipuleucel-T (APC8015)FDA Link 04/2016 - 06/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2015 - 08/2012

Therapy/Procedure

119	Therapeutics 10/2022 - 12/2007
58	Drug Therapy (Chemotherapy) 06/2022 - 01/2004
28	Immunotherapy 06/2022 - 11/2014
26	Nephrectomy 01/2022 - 12/2010
12	Neoadjuvant Therapy 01/2022 - 12/2007
12	Cystectomy 01/2022 - 04/2008
8	Castration 01/2022 - 01/2010
6	Adjuvant Chemotherapy 01/2021 - 09/2012
4	Lymph Node Excision (Lymph Node Dissection) 01/2021 - 05/2015
4	Aftercare (After-Treatment) 01/2021 - 01/2013
4	Highly Active Antiretroviral Therapy (HAART) 02/2009 - 03/2008
3	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 04/2008
2	Metastasectomy 01/2021 - 11/2014
2	Nephroureterectomy 01/2021 - 01/2021